Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

Multiple doses of alemtuzumab for immunosuppressive therapy of patients with hematologic malignancies and hematopoietic stem cell transplant have been associated with a high rate of infection. In transplantation, limited alemtuzumab dosing has been successfully used as induction immunosuppression. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Adam, Young, Jo-Anne H., Kandaswamy, Raja, Berglund, Danielle, Knoll, Bettina M., Sieger, Gretchen, Cavert, Winston, Matas, Arthur, Obeid, Karam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569440/
https://www.ncbi.nlm.nih.gov/pubmed/33101558
http://dx.doi.org/10.1155/2020/8883183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569440/
https://www.ncbi.nlm.nih.gov/pubmed/33101558
http://dx.doi.org/10.1155/2020/8883183

Ejemplares similares